Results 41 to 50 of about 25,112 (170)

Resistance to Fas-Mediated Apoptosis of Human T-Cell Lines Expressing Human T-Lymphotropic Virus Type-2 (HTLV-2) Tax Protein

Virology, 2001
The susceptibility to Fas-mediated apoptosis was evaluated in seven T-cell lines (two infected with HTLV-2, one with HTLV-1, and four HTLV-free) as well as in Jurkat cells transfected with a Tax-2 expressing vector. Fas-mediated apoptosis was significantly reduced in the HTLV-1- and HTLV-2-infected lines in comparison with the HTLV-free lines ...
G. Zehender, S. Varchetta, C. De Maddalena, C. Colasante, A. Riva, L. Meroni, M. Moroni, M. Galli   +7 more
openaire   +4 more sources

Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort study

Retrovirology, 2004
Background HTLV-I is associated with adult T-cell leukemia, and both HTLV-I and -II are associated with HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Smith James W, Garratty George, Nass Catharie C, Wright David J, Wang Baoguang, Orland Jennie R, Newman Bruce, Smith Donna M, Murphy Edward L   +8 more
doaj   +1 more source

HIV-1 and HTLV-1 Transmission Modes: Mechanisms and Importance for Virus Spread

Viruses, 2022
So far, only two retroviruses, human immunodeficiency virus (HIV) (type 1 and 2) and human T-cell lymphotropic virus type 1 (HTLV-1), have been recognized as pathogenic for humans. Both viruses mainly infect CD4+ T lymphocytes.
Svetlana Kalinichenko, Dmitriy Komkov, Dmitriy Mazurov   +2 more
doaj   +1 more source

The prevalence of human T‐lymphotropic virus type 1 & 2 (HTLV‐1/2) in South African blood donors

Vox Sanguinis, 2019
Background and objectivesDonated blood is not currently screened for human T‐cell lymphotropic virus (HTLV) in South Africa. Several small studies have detected HTLV‐1 in South Africa, but prevalence by geographic region or population group is unavailable.Materials and MethodsWe performed a large seroprevalence study of South African blood donors ...
Marion Vermeulen, Wendy Sykes, Charl Coleman, Brian Custer, Genevieve Jacobs, Jabulisile Jaza, Zhanna Kaidarova, Carol Hlela, Antoine Gessain, Olivier Cassar, Colwyn Poole, Charlotte Ingram, Edward L. Murphy, Ravi Reddy   +13 more
openaire   +5 more sources

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Pathways of cell-cell transmission of HTLV-1

Frontiers in Microbiology, 2012
The deltaretroviruses human T-cell lymphotropic virus type 1 (HTLV-1) and human T-cell lymphotropic virus type 2 (HTLV-2) have long been believed to differ from retroviruses in other genera by their mode of transmission.
Claudine ePique, Claudine ePique, Kathryn Suzanne Jones   +2 more
doaj   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Silencers of HTLV-1 and HTLV-2: the pX-encoded latency-maintenance factors

Retrovirology, 2019
Of the members of the primate T cell lymphotropic virus (PTLV) family, only the human T-cell leukemia virus type-1 (HTLV-1) causes disease in humans—as the etiological agent of adult T-cell leukemia/lymphoma (ATLL), HTLV-1-associated myelopathy/tropical ...
Robert Harrod
doaj   +1 more source

Nectin-2 Acts as a Viral Entry Mediated Molecule That Binds to Human Herpesvirus 6B Glycoprotein B

Viruses, 2022
Human herpesvirus 6B (HHV-6B) is a T-lymphotropic virus and the etiological agent of exanthem subitum. HHV-6B is present in a latent or persistent form after primary infection and is produced in the salivary glands or transmitted to this organ.
Hirohito Ogawa, Daisuke Fujikura, Hikaru Namba, Nobuko Yamashita, Tomoyuki Honda, Masao Yamada   +5 more
doaj   +1 more source

Risk factors and epidemiology of human T-lymphotropic virus types 1 and 2 in US blood donors [PDF]

Retrovirology, 2015
Blood donations in the US are routinely screened for markers of human T-lymphotropic virus (HTLV). Seroprevalence and risk factors associated with HTLV-1 and -2 infection from the US Retrovirus Epidemiology Donor Study (REDS-II) Transfusion-Transmitted Viral Infection (TTVI) Rate and Risk Factor Study are reported.
Vahidnia, Farnaz, Stramer, Susan L, Kessler, Debra A, Krysztof, David E, Dodd, Roger Y, Notari, Ed, Glynn, Simone, Custer, Brian   +7 more
openaire   +1 more source